A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime/Boost Vaccine Regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adult Participants.

Trial Profile

A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Heterologous Prime/Boost Vaccine Regimens (NYVAC-B/rAd5 vs. rAd5/NYVAC-B) in Healthy, HIV-1 Uninfected, Ad5 Seronegative Adult Participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2013

At a glance

  • Drugs HIV vaccine (Primary) ; NYVAC-B (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Planned end date 1 Oct 2012 added as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top